Patients With Kidney Disease Reach Target Glucose With Low Incidence of Hypoglycemia When IV Insulin Is Managed on eGlycemic Management System Glucommander

Patients With Kidney Disease Reach Target Glucose With Low Incidence of Hypoglycemia When IV Insulin Is Managed on eGlycemic Management System Glucommander

Presentation

American Diabetes Association Scientific Sessions

Date

June 2015

Authors

Joe Aloi,1 Raymie McFarland,2 Robby Booth,2 Melanie Mabrey,2 Paul Chidester,3 Amy Henderson,2 Andrew Rhinehart2

Objective

Glucose control in hospitalized patients with kidney disease can be challenging. The impact of decreasing Glomerular Filtration Rate (GFR) on active insulin time may lead to accumulation of insulin and subsequent life-threatening hypoglycemia that is often difficult to correct. Thus, providers must be judicious in the use of insulin in this population. We studied the use of Glucommander, (GM) a cloud based insulin algorithm, to treat hyperglycemia in patients with kidney disease.

Methods

We retrospectively evaluated the efficacy and safety of using GM for patients with kidney disease who required IV insulin using the following inclusion criteria:

  • Adult patients with type 1 or 2 diabetes mellitus.
  • 2 blood glucoses (BG) >180 mg/dL or 1 BG >250 mg/dL.
  • Creatinine >3.0 mEq/L.
  • 716 patient charts over 10 months were available.
  • Glucose target was set at 140-180 mg/dL.

Results

The mean insulin infusion treatment time was 51.5 hours. 35,915 BG readings were analyzed with an average starting BG of 511 mg/dl (+/- 277) and 155 mg/dL (+/- 53) while patients were on GM. Hypoglycemia <40 mg/dL was 0.1% and <70 mg/dL was 1.0%. Time to target was 6.8 hours (+/- 1.3) and the percent of BG in the prescribed target range of 140-180 mg/dL was 72.5%.


Patients 716
Mean Treatment Time 51.5 +/- 21 Hours
Average Initial BG 511 +/- 277 mg/dL
Average BG on GM 155 +/- 53 mg/dL
Average Time to Target 6.8 Hours +/-1.3
Number of BG Readings 35,915

Conclusion

This study demonstrates patients with kidney disease can reach target glucose in a reasonable timeframe with a very low incidence of hypoglycemia. In conclusion, Glucommander can efficaciously, but more importantly safely, reduce and control blood glucose in patients with decreased renal function.

Affiliations

  1. Wake Forest Baptist Medical Center, Winston Salem, North Carolina.
  2. Glytec, Waltham, Massachusetts.
  3. Sentara Healthcare System, Norfolk, Virginia.
  4. Duke University School of Nursing, Durham, North Carolina.
Request Demo